A novel anti-interferon antibody sustained skin response in dermatomyositis

Design

Phase 2 double-blind study plus 52-week open-label extension (combined 92 weeks)

Population

Small cohort of adults with moderate-to-severe dermatomyositis (16 in the pooled skin set)

Primary outcome

Treatment-emergent adverse events; secondary CDASI-Activity change

Effect

Median CDASI-Activity change about −23.5 in the pooled skin set, sustained to week 92

Dazukibart is a monoclonal antibody against interferon-β, a cytokine central to dermatomyositis skin disease. This analysis pooled a 24-week phase 2 double-blind study with a 52-week open-label extension and 16-week follow-up, reporting on a small cohort with at least moderate cutaneous activity.

Cutaneous disease activity, scored on the CDASI, improved substantially and the gains were sustained through 92 weeks, with a median fall of about 23 points on the pooled skin set. Adverse events were mostly mild or moderate, with no treatment-related serious events or discontinuations, and improvement persisted into the post-treatment follow-up.

For refractory cutaneous dermatomyositis — often steroid- and immunosuppressant-dependent — a durable, well-tolerated targeted option would matter. But this is early: very few patients, and the long-term data come from an uncontrolled open-label extension rather than a randomised comparison. It is a signal to watch in later-phase trials, not a treatment to reach for yet.

• Cutaneous activity (CDASI) fell by a median of about 23 points in the pooled skin set and the gains held to week 92.
• Adverse events were mostly mild or moderate, with no treatment-related serious events or discontinuations.
• Improvement persisted during the 16-week post-treatment follow-up.
• Regard it as an early-phase signal for refractory cutaneous dermatomyositis, not a current treatment option.

Why it matters

It targets the interferon pathway that drives dermatomyositis skin disease, where current options are blunt and often toxic.

Don't overread it

Very small and, in the extension phase, open-label and uncontrolled — this cannot establish efficacy, only sustained signal and tolerability.

The statistics, in plain English

A roughly 23-point CDASI fall is a large change on that scale, but the numbers come from a handful of patients and, in the extension, without a control group — so the size is encouraging but unreliable as an effect estimate.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.